Table 1.
Demographic, Clinical and Imaging Characteristics of the PLS, PSP and Control Groups
| Median (range) | ||||
|---|---|---|---|---|
| Characteristic | Controls (n=20) | PLS (n=3) | PSP (n=10) | P value (PLS vs. PSP) |
| Demographics | ||||
| Female sex, No. (%) | 11 (55) | 1 (33) | 6 (60) | 0.60 |
| Age at disease onset, y | NA | 67 (60–68) | 65 (54–75) | 0.93 |
| Age at examination, y | 71.5 (51–78) | 70 (64–70) | 69 (58–79) | 0.93 |
| Disease duration, y | NA | 4 (2–4) | 4 (2–9) | 0.55 |
| Clinical features | ||||
| FBI (/72)a | NA | 0 (0–4) | 9 (0–28) | 0.07 |
| FAB (/18) a | NA | 17 (16–18) | 13 (10–16) | 0.02 |
| MMSE (/30) a | NA | 30 (29–30) | 29 (22–30) | 0.19 |
| UPDRS III (/132) a | NA | 51 (25–70) | 46 (18–59) | 0.80 |
| Pseudobulbar affect, No. (%) | NA | 3 (100) | 1 (10) | 0.01 |
| MND features | NA | 3 (100) | 2 (20) | 0.01 |
| Fractional anisotropy of white matter tracts | ||||
| CST | 0.63 (0.50–0.81) | 0.49 (0.43–0.55) | 0.60 (0.51–0.70) | 0.04 |
| SCP | 0.86 (0.72–0.91) | 0.75 (0.68–0.78) | 0.63 (0.53–0.80) | 0.09 |
| BCC | 0.72 (0.61–0.83) | 0.66 (0.56–0.73) | 0.60 (0.45–0.75) | 0.50 |
| CST/SCP ratio | 0.72 (0.58–0.94) | 0.66 (0.55–0.81) | 0.89 (0.76–1.17) | 0.02 |
Abbreviations: BCC, body of the corpus callosum; CST, corticospinal tract; FAB, frontal assessment battery; FBI, frontal behavioral inventory; MMSE, mini mental status examination; MND, motor neuron disease; NA, not applicable; PLS, primary lateral sclerosis; PSP, progressive supranuclear palsy; SCP, superior cerebellar peduncle; UPDRS III, United Parkinson’s disease rating scale.
a
Highest possible score on the scales represented as (/score).